Patents by Inventor Xinmin Gan

Xinmin Gan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METABOLICALLY STABLE PRODRUGS
    Publication number: 20210401992
    Abstract: Provided are prodrugs of various therapeutic agents that provide enhanced bioavailability of the therapeutic agent, and methods of treatment conditions in a subject by administration of the one or prodrugs. As provided herein a prodrug includes a therapeutic agent covalently attached to a cap, the cap having a structure according to formula (I) where: R1 is a branched or linear substituted or unsubstituted C2-C6 alkyl, alkenyl, or alkynl; X is —S(0)2-; R2 is a branched or linear substituted or unsubstituted C4-C20 alkyl, alkenyl, or alkynyl; and R3 is —H, C3-C5 cycloalkyl, C3-C5 cycloheteroalkyl, —C(CH3)3, —CF3, —C(CF3)3, or a substituted or unsubstituted phenyl.
    Type: Application
    Filed: June 26, 2019
    Publication date: December 30, 2021
    Applicants: TSRL, Inc., Regents of the University of Michigan
    Inventors: Elke D. Lipka, Eric Simon, Andy D. White, Kim M. Hutchings, Xinmin Gan
  • Amlexanox analogs
    Patent number: 10214536
    Abstract: Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 26, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Hollis D. Showalter, Alan R. Saltiel, John J. Tesmer, Xinmin Gan
  • AMLEXANOX ANALOGS
    Publication number: 20170217980
    Abstract: Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 3, 2017
    Inventors: Hollis D. Showalter, Alan R. Saltiel, John J. Tesmer, Xinmin Gan
  • Bicyclic and tricyclic compounds as KAT II inhibitors
    Patent number: 8183238
    Abstract: Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: May 22, 2012
    Assignee: Pfizer Inc.
    Inventors: Michelle M. Claffey, Amy B. Dounay, Matthew M. Hayward, Suobao Rong, Patrick R. Verhoest, Jamison B. Tuttle, Xinmin Gan
  • Bicyclic And Tricyclic Compounds As KAT II Inhibitors
    Publication number: 20100324043
    Abstract: Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 23, 2010
    Inventors: Michelle M. Claffey, Amy B. Dounay, Matthew M. Hayward, Suobao Rong, Patrick R. Verhoest, Jamison B. Tuttle, Xinmin Gan